ClinicalTrials.gg
RecruitingNCT07252739Updated Nov 10, 2026

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

A Phase 2 interventional study of MK-1084 and Pembrolizumab in Malignant Neoplasm, sponsored by Merck Sharp & Dohme LLC. Recruiting at 40 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Nov 10, 2026First site in Poland2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.

02

Conditions studied

  • Malignant Neoplasm

Browse trials for

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 140 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has or cytologically confirmed diagnosis of advanced or nonsquamous Non-Small Cell Lung Cancer (NSCLC)
  • Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations
  • Can provide an sample or newly obtained core, incisional, excisional biopsy of a tumor lesion not previously irradiated
  • Has recovered to ≤Grade 1 or baseline from any Adverse events (AEs) due to previous anticancer therapies and/or ≤Grade 2 neuropathy and/or endocrine-related AEs adequately treated with hormone replacement
  • Has well controlled (HIV) on antiretroviral therapy (ART) if HIV-infected
  • Has undetectable (HBV) viral load and have received HBV antiviral therapy for at least 4 weeks if hepatitis B surface antigen (HBsAg) positive
  • Has undetectable (HCV) viral load if HCV-infected

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
  • Has -infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has active inflammatory bowel disease requiring medication or previous clear history of inflammatory bowel disease
  • Has uncontrolled, cardiovascular disease or cerebrovascular disease, including Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of interval corrected for heart rate by Fridericia's formula (QTcF) interval to >470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
  • Has received prior systemic anticancer therapy for advanced or NSCLC
  • Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
  • Has received previous treatment with an agent targeting KRAS
  • Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from AE associated with anticancer therapy before allocation/randomization
  • Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
  • Has a known additional that is progressing or has required active treatment within the past 3 years
  • Has a known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has an active disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening
  • Has a history of stem cell/solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Arm A- Pembrolizumab + MK-1084

    Participants receive 400 mg of Pembrolizumab every 6 weeks and MK-1084 dose regimen.

    Drug: MK-1084 · Biological: Pembrolizumab

  • Experimental
    Arm B- Pembrolizumab + MK-1084 + Cetuximab

    Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and Cetuximab 500 mg/m\^2 every 2 weeks.

    Drug: MK-1084 · Biological: Pembrolizumab · Biological: Cetuximab

  • Experimental
    Arm C- Pembrolizumab + MK-1084 + sacituzumab tirumotecan (sac-TMT)

    Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and 4 mg/kg sacituzumab tirumotecan (sac-TMT) every 2 weeks.

    Drug: MK-1084 · Biological: Pembrolizumab · Biological: Sacituzumab tirumotecan (sac-TMT) · Drug: Rescue medication

Interventions

  • Oral Administration

  • BiologicalPembrolizumab

    Intravenous administration

    Also known as: Keytruda, MK-3475

  • BiologicalCetuximab

    Intravenous administration

  • Injection powder for intravenous infusion

    Also known as: MK-2870, SKB264

  • DrugRescue medication

    Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 \[Hl\] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, and granulocyte colony-stimulating factor (G-CSF). A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with a Dose Limiting Toxicity (DLT)

    A DLT is defined as the occurrence of protocol-specified toxicities if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration, excluding toxicities clearly not related to the drug.

    Time frame: Up to approximately 21 days

  2. Percentage of Participants who Experience at Least One Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 84 months

  3. Percentage of Participants who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 84 months

  4. Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.

    Time frame: Up to approximately 84 months

Secondary outcomes

  1. Duration of Response (DOR) per RECIST 1.1 as assessed by BICR

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to approximately 84 months

  2. Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

    Time frame: Up to approximately 84 months

  3. Overall Survival (OS)

    OS, defined as the time from first dose or randomization (depending on study period) to death due to any cause. OS will be presented.

    Time frame: Up to approximately 84 months

  4. Area Under the Concentration-Time Curve (AUC) for MK-1084

    Blood samples will be collected to determine the AUC of MK-1084.

    Time frame: At designated timepoints (up to approximately 44 days)

  5. Maximum Concentration (Cmax) of MK-1084

    Blood samples will be collected to estimate Cmax of MK-1084.

    Time frame: At designated timepoints (up to approximately 44 days)

  6. Trough Concentration (Ctrough) of MK-1084

    Blood samples will be collected to determine the Ctrough of MK-1084.

    Time frame: At designated timepoints (up to approximately 84 months)

07

Study locations

39 of 40 sites recruiting
  • Clermont Oncology Center ( Site 0041)
    Clermont, Florida 34711, United States
    Recruiting
    • Study Coordinator · Contact386-538-3169
  • Sanford Health Roger Maris Cancer Center ( Site 0039)
    Fargo, North Dakota 58102, United States
    Recruiting
    • Study Coordinator · Contact701-234-2000
  • Sanford Cancer Center Oncology Clinic ( Site 0038)
    Sioux Falls, South Dakota 57104, United States
    Recruiting
    • Study Coordinator · Contact605-328-8000
  • Fundacion Arturo Lopez Perez ( Site 0167)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact56224205098
  • Centro de Oncología de Precisión ( Site 0160)
    Santiago, Region M. de Santiago 7560908, Chile
    Recruiting
    • Study Coordinator · Contact+56991612199
  • Bradfordhill ( Site 0168)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact+56998744662
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)
    Nanjing, Jiangsu 210000, China
    Recruiting
    • Study Coordinator · Contact+8602568182222
  • The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306)
    Nanchang, Jiangxi 330209, China
    Recruiting
    • Study Coordinator · Contact+86 791 8631 9333
  • Zhongshan Hospital Fudan University ( Site 0319)
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Study Coordinator · Contact+8615000229853
  • West China Hospital, Sichuan University ( Site 0315)
    Chengdu, Sichuan 610066, China
    Recruiting
    • Study Coordinator · Contact+8618980602252
  • Kuopion Yliopistollinen Sairaala ( Site 0261)
    Kuopio, Northern Savonia 70200, Finland
    Recruiting
    • Study Coordinator · Contact+35817173311
  • Vaasan Keskussairaala ( Site 0263)
    Vaasa, Pohjanmaa 65130, Finland
    Recruiting
    • Study Coordinator · Contact+358405533545
  • Turku University Hospital ( Site 0262)
    Turku, Southwest Finland 20520, Finland
    Recruiting
    • Study Coordinator · Contact+35823138709
  • HYKS Syöpätautien klinikka ( Site 0260)
    Helsinki, Uusimaa 00290, Finland
    Recruiting
    • Study Coordinator · Contact+358406682951
  • Evangelismos General Hospital of Athens ( Site 0200)
    Athens, Attica 106 76, Greece
    Recruiting
    • Study Coordinator · Contact+302132041631
  • Hong Kong Integrated Oncology Centre ( Site 0232)
    Central, 0000, Hong Kong
    Recruiting
    • Study Coordinator · Contact+85237006888
  • Queen Mary Hospital ( Site 0230)
    Hong Kong, Hong Kong
    Recruiting
    • Study Coordinator · Contact+85222551727
  • Hong Kong United Oncology Centre ( Site 0231)
    Kowloon, Hong Kong
    Recruiting
    • Study Coordinator · Contact+852 2386 8002
  • Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175)
    Milan, Lombardy 20133, Italy
    Recruiting
    • Study Coordinator · Contact00390223903829
  • Deventer Ziekenhuis ( Site 0272)
    Deventer, Overijssel 7416 SE, Netherlands
    Recruiting
    • Study Coordinator · Contact+31570536437
  • Leids Universitair Medisch Centrum ( Site 0273)
    Leiden, South Holland 2333 ZA, Netherlands
    Recruiting
    • Study Coordinator · Contact+31715566376
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
    Warsaw, Masovian Voivodeship 02-781, Poland
    Recruiting
    • Study Coordinator · Contact48 22 546 23 36
  • Severance Hospital Yonsei University Health System ( Site 0080)
    Seoul, 03722, South Korea
    Recruiting
    • Study Coordinator · Contact+82222280880
  • Hospital Universitario Virgen de la Macarena ( Site 0093)
    Seville, 41009, Spain
    Recruiting
    • Study Coordinator · Contact+34 671560092
  • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351)
    Bangkok, Bangkok 10300, Thailand
    Recruiting
    • Study Coordinator · Contact+6622443461
  • Faculty of Medicine Siriraj Hospital ( Site 0350)
    Bangkok, Bangkok 10700, Thailand
    Recruiting
    • Study Coordinator · Contact+6624194488-9
  • Erciyes University ( Site 0145)
    Talas, Kayseri 38039, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact905366550924
  • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
    Adana, 1250, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+905537766235
  • Koç Üniversitesi Hastanesi ( Site 0142)
    Adana, 34010, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact08502508250-21251
  • Liv Hospital Ankara ( Site 0146)
    Ankara, 06680, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact905469299990
  • Hacettepe Universite Hastaneleri ( Site 0140)
    Ankara, 6230, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+90 312 305 50 00
  • COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139)
    Cherkasy, Cherkasy Oblast 18009, Ukraine
    Recruiting
    • Study Coordinator · Contact+380472370123
  • Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465)
    Kryvyi Rih, Dnipropetrovsk Oblast 50000, Ukraine
    Recruiting
    • Study Coordinator · Contact+380677490687
  • Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132)
    Ivano-Frankivsk, Ivano-Frankivsk Oblast 76018, Ukraine
    Recruiting
    • Study Coordinator · Contact380978411455
  • Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467)
    Kropyvnytskyi, Kirovohrad Oblast 25011, Ukraine
    Recruiting
    • Study Coordinator · Contact+380958718674
  • Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133)
    Lviv, Lviv Oblast 79059, Ukraine
    Recruiting
    • Study Coordinator · Contact+380677724757
  • Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131)
    Vinnitsya, Vinnytsia Oblast 21029, Ukraine
    Recruiting
    • Study Coordinator · Contact380953105783
  • Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137)
    Uzhhorod, Zakarpattia Oblast 88000, Ukraine
    Recruiting
    • Study Coordinator · Contact+380506847086
  • VISION PARTNER Medical Centre ( Site 0135)
    Kyiv, 03022, Ukraine
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138)
    Kyiv, 03151, Ukraine
    Recruiting
    • Study Coordinator · Contact+380671502987
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2029, 46 months after the start.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 46 months is close to that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Nov 28, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Nov 15, 2029
CompletionEst.
May 31, 2032
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed — first site in Poland
Show 2 added (1 Poland, 1 Ukraine)
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151) · Warsaw, Poland
  • LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138) · Kyiv, Ukraine
Show 1 removed
  • LIMITED LIABILITY COMPANY "MEDICAL CENTER "DOBROBUT-CLINIC" ( Site 0138) · Kyiv, Ukraine
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    2 sites added, 1 site removed — first site in Poland
    Show 2 added (1 Poland, 1 Ukraine)
    • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151) · Warsaw, Poland
    • LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138) · Kyiv, Ukraine
    Show 1 removed
    • LIMITED LIABILITY COMPANY "MEDICAL CENTER "DOBROBUT-CLINIC" ( Site 0138) · Kyiv, Ukraine
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07252739
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Dec 19, 2025
Primary completion
Nov 15, 2029 (estimated)
Completion
May 31, 2032 (estimated)
Last update
Nov 10, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calderasib · Cetuximab · Sacituzumab tirumotecan

Start the discussion